Mizuho Raises Price Target for Salix Pharmaceuticals Ltd.

In a report released Tuesday, Mizuho analyst Mario Corso covering Salix Pharmaceuticals Ltd.

increases his firm's price target by 15 percent from $131 to $151. Analyst at Mizuho are bullish on Xifaxan IBS top line data, anticipating approval in the first half of 2015. Salix's Xifaxan was measured as statistically significant, in a study measuring response rates compared to placebo. Two more drugs targets are in stage for an NDA resubmission in the next few weeks and approval is projected for the first half of 2015.